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Despite recent scientific advances, most rare genetic diseases — including most neuro-
muscular diseases — do not currently have curative gene-based therapies available.
However, in some cases, such as vitamin, cofactor or enzyme deficiencies, channelopa-
thies and disorders of the neuromuscular junction, a confirmed genetic diagnosis pro-
vides guidance on treatment, with drugs available that may significantly alter the disease
course, improve functional ability and extend life expectancy. Nevertheless, many treat-
able patients remain undiagnosed or do not receive treatment even after genetic diagno-
sis. The growth of computer-aided genetic analysis systems that enable clinicians to
diagnose their undiagnosed patients has not yet been matched by genetics-based deci-
sion-support systems for treatment guidance. Generating a ‘treatabolome’ of treatable
variants and the evidence for the treatment has the potential to increase treatment rates
for treatable conditions. Here, we use the congenital myasthenic syndromes (CMS), a
group of clinically and genetically heterogeneous but frequently treatable neuromuscular
conditions, to illustrate the steps in the creation of a treatabolome for rare inherited dis-
eases. We perform a systematic review of the evidence for pharmacological treatment of
each CMS type, gathering evidence from 207 studies of over 1000 patients and stratifying
by genetic defect, as treatment varies depending on the underlying cause. We assess the
strength and quality of the evidence and create a dataset that provides the foundation for
a computer-aided system to enable clinicians to gain easier access to information about
treatable variants and the evidence they need to consider.
Introduction
Rare genetic disorders are individually uncommon but collectively frequent, affecting as many as 1 in
17 people [1]. While most rare diseases do not currently have curative gene-based therapies, in a small
but increasing number of cases, a confirmed genetic diagnosis immediately provides guidance on
treatment, in some cases significantly altering the disease course, improving functional ability and
quality of life, and extending life expectancy. Marketed therapies or, in some cases, even a commonly
available drug may provide effective or even curative therapy by replacing a deficient enzyme or restor-
ing a biological function despite not correcting the genetic code. Examples include metabolic diseases
(Gaucher, Fabry, and Pompe) where enzyme replacement therapies are available [2], channelopathies
of brain, nerve, neuromuscular junction and muscle where there are effective drugs to prevent brain
damage or muscle weakness [3], or inborn errors of metabolism where severe organ damage and intel-
lectual disability can be prevented or reduced through dietary mechanisms or specific vitamin and
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cofactor replacement [4]. Furthermore, genetic therapies in which the gene itself is not repaired but defective
transcription is targeted via read-through therapies or exon skipping have recently been developed and gained
marketing authorization for rare neuromuscular diseases such as Duchenne muscular dystrophy [5], amyloid
neuropathy [6,7] and spinal muscular atrophy [8]. In other cases, non-pharmacological treatment and
follow-up, such as regular cardiac monitoring, or specific interventions, such as implantation of a pacemaker or
implantable cardioverter defibrillator, may be indicated owing to the risk a certain mutation confers [9]; or a
particular drug may be contraindicated owing to mutation-specific drug interactions or severe adverse events of
certain drugs associated with genomic variants such as malignant hyperthermia [10].
Unfortunately, the lack of information and expertise that disproportionately affects rare disease means that
not all patients harboring such treatable variants are put onto the appropriate treatment even when their diag-
nosis is confirmed, meaning that they miss out on receiving the best available care and may suffer harm and
potentially avoidable risk to life if the potential for treatment is not recognized and acted upon in a timely way.
As increasing numbers of patients are diagnosed through next-generation sequencing in research projects or
within their national healthcare systems, it becomes ever more crucial to enable flagging of potentially treatable
cases at a gene or variant level in much the same way as progress has already been made in flagging pathogen-
icity inferences, so that when a diagnosis is made, the treatment options are immediately accessible to the clin-
ical end-user and the patient rapidly receives the best care. At present, however, this knowledge is largely
available only in ‘human-readable’ scientific publications or in expert practice and not captured in computer-
accessible form that would allow automatic recognition and flagging in analysis and decision-support systems.
The transformation of human-readable expert knowledge into electronic decision-support systems must
begin with a systematic review of the evidence available in order to accurately assess levels of confidence about
particular interventions and minimize potential error and bias. If collected with due attention not only to the
treatment but also to the genetic background of the participants, the evidence gathered through such a review
can be incorporated into a database that serves as an information source for genomic analysis systems and that
can provide the input for flagging of potentially treatable variants as described above. This approach, which we
have termed the ‘treatabolome’, is the focus of research within projects such as Solve-RD [11] as part of a
broader strategy not only to increase diagnostic rates through novel sequencing methodologies but also to
increase the impact of diagnosis by increasing the speed with which patients receive the most appropriate treat-
ment for their condition.
In this present work, we aimed to create a proof of concept of the treatabolome by performing a systematic
review of a defined set of rare inherited neuromuscular conditions known as the congenital myasthenic syn-
dromes (CMS), many of which are amenable to treatment, and capturing the output of the review in a format
suitable for transformation into a computer-readable database.
The systematic review
Background
Features of CMS
CMS are a heterogeneous group of rare inherited neuromuscular disorders characterized by fatigable weakness
of skeletal muscle owing to compromised function of the neuromuscular junction (NMJ). The phenotype is
caused by failure of transmission across this synapse connecting the nerve with the muscle, whereby an incom-
ing nerve stimulus does not consistently lead to muscle excitation and contraction. Neuromuscular transmis-
sion is mediated by the generation of an action potential causing the release of acetylcholine from the nerve
terminal into the synaptic cleft, its binding to the acetylcholine receptor (AChR) with the opening of its ion
channel and the enzymatic breakdown of acetylcholine by acetylcholinesterase (AChE; Figure 1).
Pathophysiological mechanisms acting on any part of this chain and resulting in a reduction in the amount of
acetylcholine released, the impairment of the AChR, reduction in the number of receptors or defective break-
down of acetylcholine may lead to CMS. The majority of CMS types are caused by defects in the AChR itself,
but they can also result from causative variants affecting presynaptic proteins or proteins associated with the
synaptic basal lamina or variants causing defects in endplate development and maintenance or defects in
protein glycosylation. Defective neuromuscular transmission presents clinically as fatigable weakness due to
increasing impairment of transmission across the NMJ with repeated activation.
The majority of cases of CMS show disease onset within the first year of life, but in some patients, symptoms
do not appear until later in childhood or even adulthood. Additional symptoms may include weakness of
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ocular, facial and bulbar muscles causing ptosis, ophthalmoplegia and feeding difficulties; respiratory difficulties
including episodic apnea; and joint contractures. With the advent of next-generation sequencing (NGS), the
number of genetic defects reported as causative of a CMS phenotype has increased dramatically, with over 30
genes now implicated [12]. Although all CMS subtypes share the common features of NMJ pathology and fatig-
able weakness, the severity of the disease, its course of progression, specific phenotypic manifestations and
effective treatments are highly variable between subtypes and are often gene- or even mutation-specific.
Treatment of CMS
Unlike the related autoimmune disease myasthenia gravis, CMS is not caused by an immune response, and
immunomodulating therapies are therefore not effective [13]. Most CMS subtypes are nevertheless amenable to
some form of pharmacotherapy, but pharmacological treatment varies by subtype, with the drugs appropriate
for one type potentially making another worse [14]. Treatment strategies are illustrated in Figure 1 and Table 1,
and are broadly dependent on whether it is beneficial to increase the amount of acetylcholine available in the
synaptic cleft (for which commonly administered therapies include AChE inhibitors such as pyridostigmine,
which inhibits acetylcholine breakdown, and the potassium-channel blocker 3,4-diaminopyridine, which
increases the quantal release of acetylcholine) or to shorten the excessive duration of synaptic current in slow-
channel syndromes by reducing the channel-open time (for which the open-channel blockers fluoxetine and
quinidine may be used). β2 adrenergic receptor agonists such as ephedrine and salbutamol (albuterol) are also
widely prescribed for CMS, having serendipitously been discovered in the 1930s to be beneficial in autoimmune
Figure 1. Localization of CMS types and therapeutic strategies.
CMS types are stratified according to the location of the genetic defect into presynaptic, synaptic, and basal
lamina-associated, postsynaptic and other, and then further stratified by genetic and functional defect. Therapeutic strategies
act on different parts of the NMJ and are effective in different types.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
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Table 1 CMS treatment recommendations stratified by type, including key references and total number of primary reports evaluated
Gene
involved Descriptive name
First-line
treatment
recommendation
Supplemental
treatment
recommendation
1
Supplemental
treatment
recommendation
2
Likely
ineffective
Avoid
treatment
(may worsen)
Expert summary of the
evidence
Key
reference
Number of
publications
AGRN Congenital myasthenic
syndrome due to agrin
deficiency caused by
pathogenic variants in AGRN
Salbutamol or
ephedrine
Pyridostigmine Small number of reported
cases; exploratory
treatment with
β2-adrenergic receptor
agonists
[56] 7
ALG14 Congenital myasthenic
syndrome due to a defect of
glycosylation caused by
pathogenic variants in ALG14
Pyridostigmine 3,4-DAP Small number of reported
cases; exploratory
treatment with an
acetylcholinesterase
inhibitor
[57] 2
ALG2 Congenital myasthenic
syndrome due to a defect of
glycosylation caused by
pathogenic variants in ALG2
Pyridostigmine 3,4-DAP Small number of reported
cases; exploratory
treatment with an
acetylcholinesterase
inhibitor
[57] 1
CHAT Congenital myasthenic
syndrome due to endplate
choline acetyltransferase
deficiency caused by
pathogenic variants in CHAT
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Acetylcholinesterase
inhibitors recommended
including in
oligosymptomatic
patients to reduce EA
[58] 18
CHRNA1 Slow-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in
CHRNA1
Fluoxetine or
quinidine
Pyridostigmine Channel blocker
recommended; avoid
acetylcholinesterase
inhibitors
[35,42] 8
CHRNA1 Fast-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by pathogenic
variants in CHRNA1
Pyridostigmine Salbutamol or
ephedrine
3,4-DAP Fluoxetine or
quinidine
Acetylcholinesterase
inhibitors recommended;
may require add-on
second-line therapy
[59] 4
CHRNA1 Congenital myasthenic
syndrome due to primary
acetylcholine receptor
deficiency caused by
pathogenic variants in
CHRNA1
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitor
[40] 3
CHRNB1 Slow-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in
CHRNB1
Fluoxetine or
quinidine
Pyridostigmine Channel blocker
recommended; avoid
acetylcholinesterase
inhibitors
[35,42] 5
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Table 1 CMS treatment recommendations stratified by type, including key references and total number of primary reports evaluated
Gene
involved Descriptive name
First-line
treatment
recommendation
Supplemental
treatment
recommendation
1
Supplemental
treatment
recommendation
2
Likely
ineffective
Avoid
treatment
(may worsen)
Expert summary of the
evidence
Key
reference
Number of
publications
CHRNB1 Fast-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by pathogenic
variants in CHRNB1
Pyridostigmine Salbutamol or
ephedrine
3,4-DAP Fluoxetine or
quinidine
Acetylcholinesterase
inhibitors recommended;
may require add-on
second-line therapy
[60] 1
CHRNB1 Congenital myasthenic
syndrome due to primary
acetylcholine receptor
deficiency caused by
pathogenic variants in
CHRNB1
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitor
[36] 1
CHRND Slow-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in CHRND
Fluoxetine or
quinidine
Pyridostigmine Channel blocker
recommended; avoid
acetylcholinesterase
inhibitors
[35,42] 2
CHRND Fast-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by pathogenic
variants in CHRND
Pyridostigmine Salbutamol or
ephedrine
3,4-DAP Fluoxetine or
quinidine
Acetylcholinesterase
inhibitors recommended;
may require add-on
second-line therapy
[59] 4
CHRND Congenital myasthenic
syndrome due to primary
acetylcholine receptor
deficiency caused by
pathogenic variants in
CHRND
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitor
[12] 2
CHRND Congenital myasthenic
syndrome due to defects in
acetylcholine receptor
clustering caused by
pathogenic variants in
CHRND
Pyridostigmine Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitor
[61] 1
CHRNE Slow-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in CHRNE
Fluoxetine or
quinidine
Pyridostigmine Channel blocker
recommended; avoid
acetylcholinesterase
inhibitors
[35,42] 11
CHRNE Fast-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by pathogenic
variants in CHRNE
Pyridostigmine Salbutamol or
ephedrine
3,4-DAP Fluoxetine or
quinidine
Acetylcholinesterase
inhibitors recommended;
may require add-on
second-line therapy
[59] 6
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Table 1 CMS treatment recommendations stratified by type, including key references and total number of primary reports evaluated
Gene
involved Descriptive name
First-line
treatment
recommendation
Supplemental
treatment
recommendation
1
Supplemental
treatment
recommendation
2
Likely
ineffective
Avoid
treatment
(may worsen)
Expert summary of the
evidence
Key
reference
Number of
publications
CHRNE Congenital myasthenic
syndrome due to primary
acetylcholine receptor
deficiency caused by
pathogenic variants in CHRNE
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Acetylcholinesterase
inhibitors recommended;
may require add-on
second-line therapy
[34] 40
CHRNE Congenital myasthenic
syndrome with kinetic defect
due to reduced ion channel
conductance caused by
pathogenic variants in CHRNE
Pyridostigmine Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitor
[62] 1
COL13A1 Congenital myasthenic
syndrome due to collagen 13
defects caused by pathogenic
variants in COL13A1
3,4-DAP Salbutamol or
ephedrine
Pyridostigmine Small number of reported
cases; exploratory
treatment with β2
adrenergic receptor
agonists and 3,4-DAP
[63] 2
COLQ Congenital myasthenic
syndrome due to endplate
acetylcholinesterase
deficiency caused by
pathogenic variants in COLQ
Salbutamol or
ephedrine
Pyridostigmine β2 adrenergic receptor
agonists recommended;
avoid
acetylcholinesterase
inhibitors
[31] 35
DOK7 Congenital myasthenic
syndrome due to defects in
docking protein 7 caused by
pathogenic variants in DOK7
Salbutamol or
ephedrine
Pyridostigmine β2 adrenergic receptor
agonists recommended;
avoid
acetylcholinesterase
inhibitors
[27] 40
DPAGT1 Congenital myasthenic
syndrome due to a defect of
glycosylation caused by
pathogenic variants in
DPAGT1
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Acetylcholinesterase
inhibitors recommended.
May see additional
benefit with addition of
3,4-DAP and salbutamol
[64] 7
GFPT1 Congenital myasthenic
syndrome due to a defect of
glycosylation caused by
pathogenic variants in GFPT1
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Acetylcholinesterase
inhibitors recommended.
May see additional
benefit with the addition
of 3,4-DAP and
salbutamol; no effect on
dystrophy expected
[38] 10
GMPPB Congenital myasthenic
syndrome due to a defect of
glycosylation caused by
pathogenic variants in
GMPPB
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Acetylcholinesterase
inhibitors recommended.
May see additional
benefit with the addition
of 3,4-DAP and
salbutamol; no effect on
dystrophy expected
[65] 6
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Table 1 CMS treatment recommendations stratified by type, including key references and total number of primary reports evaluated
Gene
involved Descriptive name
First-line
treatment
recommendation
Supplemental
treatment
recommendation
1
Supplemental
treatment
recommendation
2
Likely
ineffective
Avoid
treatment
(may worsen)
Expert summary of the
evidence
Key
reference
Number of
publications
LAMB2 Congenital myasthenic
syndrome due to laminin β2
deficiency caused by
pathogenic variants in LAMB2
Salbutamol or
ephedrine
Small number of reported
cases; exploratory
treatment with β2
adrenergic receptor
agonists
[66] 1
LRP4 Congenital myasthenic
syndrome due to defects in
low-density lipoprotein
receptor-related protein 4
caused by pathogenic
variants in LRP4
Salbutamol or
ephedrine
Pyridostigmine Small number of reported
cases; exploratory
treatment with β2
adrenergic receptor
agonists
[67] 2
MUSK Congenital myasthenic
syndrome due to defects in
MuSK caused by pathogenic
variants in MUSK
Salbutamol or
ephedrine
Pyridostigmine Small number of reported
cases; exploratory
treatment with β2
adrenergic receptor
agonists
[68] 11
MYO9A Congenital myasthenic
syndrome due to a defect in
Myosin 9A caused by
pathogenic variants in MYO9A
Pyridostigmine Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitors
[69] 2
PLEC1 Congenital myasthenic
syndrome due to plectin
deficiency caused by
pathogenic variants in PLEC1
Pyridostigmine Small number of reported
cases
[70] 2
PREPL Congenital myasthenic
syndrome due to pathogenic
variants in PREPL that predict
reduced filling of synaptic
vesicles with ACh
Pyridostigmine Small number of reported
cases;
acetylcholinesterase
inhibitors possibly
beneficial in infancy
[71] 2
RAPSN Congenital myasthenic
syndrome due to endplate
rapsyn deficiency caused by
pathogenic variants in RAPSN
Pyridostigmine 3,4-DAP Salbutamol or
ephedrine
Fluoxetine Acetylcholinesterase
inhibitors recommended.
May see additional
benefit with addition of
3,4-DAP and salbutamol
[72] 40
SCN4A Congenital myasthenic
syndrome due to a sodium
channel 1.4 defect caused by
pathogenic variants in SCN4A
Pyridostigmine Acetazolamide Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitors. Acetazolamide
may be helpful for
periodic paralysis
[73] 3
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Table 1 CMS treatment recommendations stratified by type, including key references and total number of primary reports evaluated
Gene
involved Descriptive name
First-line
treatment
recommendation
Supplemental
treatment
recommendation
1
Supplemental
treatment
recommendation
2
Likely
ineffective
Avoid
treatment
(may worsen)
Expert summary of the
evidence
Key
reference
Number of
publications
SLC18A3 Congenital myasthenic
syndrome due to a vesicular
acetylcholine transporter
defect caused by pathogenic
variants in SLC18A3
Pyridostigmine Acetylcholinesterase
inhibitors may be useful
for respiratory crisis
[12] 2
SLC25A1 Congenital myasthenic
syndrome due to a
mitochondrial citrate carrier
defect caused by pathogenic
variants in SLC25A1
Pyridostigmine 3,4-DAP Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitors
[74] 1
SLC5A7 Congenital myasthenic
syndrome due to a choline
transporter defect caused by
pathogenic variants in
SLC5A7
Pyridostigmine Ephedrine Acetylcholinesterase
inhibitors recommended
[12] 4
SNAP25B Congenital myasthenic
syndrome due to a
synaptosomal-associated
protein 25 defect caused by
pathogenic variants in
SNAP25B
3,4-DAP Small number of reported
cases; exploratory
treatment with 3,4-DAP
[75] 1
SYT2 Congenital myasthenic
syndrome due to a
synaptotagmin defect caused
by a pathogenic variant in
SYT2
3,4-DAP Small number of reported
cases; exploratory
treatment with 3,4-DAP
[76] 1
UNC13A Congenital myasthenic
syndrome due to a
mammalian
unco-ordinated-13 protein
defect caused by a
pathogenic variant in
UNC13A
3,4-DAP Pyridostigmine Small number of reported
cases; exploratory
treatment with 3,4-DAP
[77] 1
VAMP1 Congenital myasthenic
syndrome due to a
vesicle-associated membrane
protein 1 defect caused by a
pathogenic variant in VAMP1
Pyridostigmine Small number of reported
cases; exploratory
treatment with
acetylcholinesterase
inhibitors
[78] 1
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myasthenia gravis [13], but despite being first-line treatment in some CMS types, their mechanism of action is
not well understood, though it is hypothesized to act as a backup to the agrin complex, stabilizing endplate
structures and reversing AChR dispersal [15].
This review investigates the evidence for pharmacological treatment of CMS. In addition to pharmacother-
apy, non-drug treatments may be appropriate in CMS. These again vary by subtype according to symptom or
specific phenotypic presentation, but may include physiotherapy, monitoring of respiratory and bulbar func-
tion, respiratory support, and gastric feeding tube if required. As with any genetic disease, genetic counseling
for the family may be warranted. This systematic review does not cover non-pharmacological treatments of
CMS.
Objectives of the systematic review
Our objectives in performing this review were to identify the available evidence relating to the effect of pharma-
cological treatment of CMS, to systematically assess the strength of the evidence according to the Centre for
Evidence-Based Medicine’s (CEBM) Oxford 2011 Levels of Evidence [16], and to link treatments to precise
genetic information at the variant level or the precise subtype level where possible. This study is designed to be
the first step in making linked genotypic and treatment information available for genomics and clinical data-
bases and computer-based expert analysis systems.
Methods
The systematic review was designed using Cochrane Collaboration methodology [17] where possible and levels
of evidence were assessed using the CEBM Oxford 2011 Levels of Evidence [16]. All steps were performed by
two independent reviewers (R.T. and H.L.) with regular consensus meetings. A third reviewer (G.B.) critically
reviewed the selected evidence and resolved disagreements. P.M. reviewed the evidence and provided input into
the generation of a computer-readable dataset for the treatabolome.
Types of participants and diseases considered
We considered evidence dealing with adults and children with a genetic diagnosis of CMS or one of its sub-
types, adopting a broad definition of CMS as any genetic neuromuscular condition manifesting with fatigable
weakness of skeletal muscle and apparent NMJ involvement [18]. We included participants with any level of
severity, age of onset and level of penetrance of phenotypic features, provided the underlying genetic defect
gave rise to an apparent CMS.
Types of evidence considered
We considered for inclusion in the full systematic review randomized or quasi-randomized controlled trials of
pharmacological treatment for CMS with defined genetic subtypes. Where no evidence from such trials was
available, we considered nonrandomized trials, observational studies, case series and case reports in order to
increase the available evidence base, while noting that such studies fall lower on the CEBM scale. For these evi-
dence types, we provide a table of the evidence (Supplementary File S1) and a narrative summary and
summary tables in the results section. Non-pharmacological interventions were out of the scope of this review.
Outcome measures
We considered all appropriate outcome measures clearly indicating (positive or negative) response to treatment,
including change in scores and measures of muscle strength, functional ability and endurance, and clinical
examination results. Studies unambiguously claiming treatment response but without providing full details of
outcome measures used were considered in the narrative summary.
Search methods for identification of studies
Literature and trial database search
To discover the available evidence covering pharmacological treatment for any congenital myasthenic syn-
drome, we performed electronic searches of the literature using several databases. Search terms, keywords, and
filtration strategies are presented in Table 1. First, to identify potential sources of evidence corresponding to the
highest CEBM evidence levels, we searched for randomized controlled trials and systematic reviews using the
Cochrane Central Register of Controlled Trials (CENTRAL) [19], the ClinicalTrials.gov [20] and EU Clinical
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
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Trials [21] registers, and the Centre for Reviews and Dissemination (CRD) database [22], which includes the
Database of Abstracts of Reviews of Effects (DARE) and NHS Economic Evaluation Database (NHS EED).
Second, we searched the PubMed database [23] using a combination of keywords designed to capture the
widest possible range of relevant literature, restricting our search to English language publications from 1980 to
the present. Third, after manually reviewing the evidence from 1 and 2 and discarding duplicates and
out-of-scope articles, we manually reviewed and extracted further relevant articles from the reference sections
of the included articles.
Data collection, extraction, and analysis
The authors independently screened titles and abstracts of the publications identified through the searches in
an unblinded manner to assess eligibility for inclusion, examining the full-text publication where abstracts were
insufficiently informative. Studies that did not meet the inclusion criteria described were excluded. Full-text
manuscripts were obtained for all studies passing the preliminary screening and used for data extraction.
Characteristics of each study were captured in a standardized data extraction form. Extracted data included
study characteristics and design, presenting the phenotype of study participants, number of participants, age
distribution, treatment characteristics: type, dose, frequency, and duration of treatment; characteristics of the
outcome measures; and affected gene and variant.
Assessment of risk of bias in included studies
Our systematic review did not uncover any randomized controlled trials or other Level 1 or 2 evidence linked
to genetically confirmed CMS; therefore, we have not carried out a formal assessment of risk of bias. According
to Cochrane methodology, we must assume a high risk of bias for all nonrandomized studies, and the CEBM
grade is correspondingly low.
Results
Our search methods resulted in an initial dataset of 918 studies to be reviewed. Three hundred and ninety were
excluded as out-of-scope based on title and abstract: the majority of these studies either focused on a related
disease that was out of scope of our review (usually autoimmune myasthenia gravis or Lambert-Eaton myasthe-
nic syndrome) or were found to be animal studies or other basic science publications with no clinical data pre-
sented. A further 222 studies were excluded after review of the full text for the same reasons as above or
because they did not present treatment data in sufficient detail for extraction. The full text of 26 studies was
not available online. The systematic review process is summarized in Figure 2.
The details of the 306 remaining studies were extracted into a data extraction form for full analysis. We ana-
lyzed open-label studies, case reports, and case series (all of which report direct clinical observation of the
patients) separately from systematic reviews and expert reviews (which summarize evidence in the light of
expert opinion). Table 1 provides key recommendations and references from the extracted data and
Supplementary File S1 provides further detail.
Randomized controlled clinical trials
One 1991 study and one 1996 study [24,25] followed a randomized, double-blind placebo-controlled approach
to 3,4-diaminopyridine administration in 4 and 11 clinically diagnosed CMS patients, respectively. Since no
patient in these studies had a genetic diagnosis, we were unable to further classify the results and cannot take
them into consideration in the treatabolome dataset, as it is not possible to establish whether the variation in
response is due to differences in the underlying genetic defect (as the authors of the 1996 study themselves
speculate). It is nevertheless worthy of note that two patients receiving placebo in the 1996 study had an appar-
ent improvement of more than 20% in some evaluation scores. While this was less than the responders receiv-
ing the active treatment, it illustrates that the placebo effect may play a role even in clinical examinations and
sounds an additional note of caution, particularly for the interpretation of individual case reports with little
long-term follow-up.
We did not find any randomized controlled studies where the genetic defect was known and so we have no
evidence of this level to include in the treatabolome dataset. All trials noted in the CENTRAL, clinicaltrials.gov,
and EU trials register are listed as results not reported and were excluded from the final analysis.
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Systematic and literature reviews
We found one Cochrane systematic review of ephedrine treatment of myasthenia [26], which included CMS as
well as acquired forms of myasthenia. This review provides a detailed narrative summary of the case reports
analyzed, but found the evidence to be of ‘insufficient quality either to support or to discourage the use of
ephedrine for these syndromes’. One systematic literature review summarizes the literature on pharmacological
treatment of DOK7 CMS [27] and concludes that treatment with salbutamol or ephedrine was beneficial in 65
of 69 patients, while other treatments trialed were beneficial in fewer cases, and in the case of AChE inhibitors
might cause worsening. This is in line with the expert recommendations for DOK7 treatment.
Case reports, case series, and open-label trials
We found a total of 207 case reports, familial case reports, case series, and prospective open-label trials that
provided information about treatment outcomes connected with genotype. Since the majority of these reports
were not treatment trials but descriptions of novel genes or variants or the variant spectrum in a particular
population, and were thus not originally designed to capture outcome measures in response to therapy, descrip-
tions of outcome measures, treatment dose, duration, and response were usually very limited or absent. We
provide the captured information in full in Supplementary File S1, and summarize the overall numbers in
Figure 2. Systematic review flow chart.
Flow diagram showing the literature evaluation process for the systematic review.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
11
Emerging Topics in Life Sciences (2019)
https://doi.org/10.1042/ETLS20180100
Table 1 and the evidence summary below. In the absence of treatment trials, this enables us to capture the
number of published cases in which the response of a particular CMS type to therapy is positive, negative or
equivocal, and may thus provide some insights into the weight of evidence that exists for a particular interven-
tion. However, this evidence must be interpreted with caution. By their very nature, all such case reports have a
high potential for subjectivity and bias. In addition, the treating clinician must remain aware that the response
of patients even with identical causative variants may not always be the same, as many of these anecdotal cases
illustrate.
Expert opinion
Expert reviews differ from systematic and literature reviews in that the authors do not attempt to systematically
capture all evidence in a format for analysis but rather to critically assess the published evidence in the light of
their own experience and expert opinion. We list the reviews discovered in full in Supplementary File S1, but
since expert opinion evolves over time, we have restricted our analysis to reviews published in the last 3 years.
This includes two recent reviews specifically focusing on treatments for CMS [13,14] as well as many compre-
hensive summaries of the current state of CMS knowledge from expert centers with many years of experience
in these rare conditions [12,28].
Evidence summary
Our systematic review revealed that all known CMS types have received pharmacotherapeutic intervention of
some kind. As is evident from Table 1, individual CMS types differ substantially in frequency and this is
reflected in the weight of evidence available, with only a handful of publications covering the most recently dis-
covered and rarest subtypes, while the more common subtypes each have numerically more substantial evidence
to support treatment. The majority of patients receive either AChE inhibitors or β2 adrenergic receptor agonists
as first-line treatment. AChE inhibitors such as pyridostigmine are commonly used in patients with AChR defi-
ciency, most of which are caused by biallelic mutations in the CHRNE gene, while they should be avoided in
patients with DOK7 and COLQ defects, where they may be ineffective or may cause clinical worsening [29–31].
DOK7 patients have been enrolled in several case series and open-label trials where they received β2 adrenergic
receptor agonists (ephedrine, salbutamol) as off-label treatment with substantial benefit [32,33]. Recently, an
increasing number of case studies report on the use of β2 adrenergic receptor agonists more generally, either as
first-line therapy or as adjunctive treatment when the first-line therapy does not achieve the desired level of
benefit alone [34]. Unlike AChE inhibitors, these drugs may take a period of weeks or months for therapeutic
benefit to be fully realized [14]. 3,4-diaminopyridine is also used more frequently as adjunctive therapy than as
the first-line treatment [13], except in some CMS types (see Table 1). Other drug treatments are only applied
to small groups of patients with specific genetic defects based on assumptions derived from experimental
models, e.g. channel blockers such as quinidine and fluoxetine in slow-channel CMS [35], where specific, dom-
inantly acting missense mutations in any of the four AChR subunit genes (CHRNE, CHRNA1, CHRNB1, and
CHRND) result in prolonged duration of channel opening, or the use of 3,4-diaminopyridine to increase acetyl-
choline quantal release in presynaptic CMS.
There is even less published information on the long-term outcomes of CMS therapies, yet patients typically
require medication over many years, possibly life-long. In the more common CMS types, there have been some
larger retrospective case series published where longer-term follow-up has been possible [36–38]. However, the
majority of case reports only cover short-term response around the time of diagnosis, and further retrospective
studies over a longer timeframe would be of value in this regard.
Genetic confirmation
Our review identified 249 case reports/series that described pharmacological treatment of patients with a clinic-
ally and physiologically diagnosed CMS, 207 of which also had genetic confirmation in one of the known CMS
causative genes. Our starting date for the data collection was 1980, a date that enabled us to capture the
growing understanding of CMS pathophysiological mechanisms and treatments but that predates the first
genetic confirmation of CMS by more than 10 years. Some of the early reports therefore did not provide
genetic details defining the underlying defect, but the variant-level evidence provided in the 207 publications,
covering over 1000 patients, can be included in the evidence for the treatabolome database. While attempts
have been made to uncover diagnostic clues including EMG results and phenotypic hallmarks that, in the
absence of a genetic test, result may still hint at specific molecular defects, and these are summarized in many
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recent reviews [39,40], phenotypic variability and overlap between CMS subtypes is such that a molecular diag-
nosis is considered the only reliable confirmation. Our review provides additional evidence to support the gen-
erally accepted position that optimal treatment does indeed vary by CMS type; and thus, knowledge of the
exact genetic defect is crucial for making the correct treatment decision, identifying the most beneficial medica-
tion and avoiding potentially detrimental effects [40]. A logical conclusion is therefore that all patients with
clinically suspected CMS should undergo genetic testing as a priority, if necessary with next-generation sequen-
cing technology: this is a widely held aim for all genetic diseases but is particularly pressing in those that are
treatable.
Discussion
Our systematic review found no randomized controlled trials of pharmacological treatment and no CEBM level
1 or 2 evidence for any genetically determined congenital myasthenic syndrome. This was not an unexpected
result, given the rarity of the condition and the fact that most pharmacological treatments for CMS are com-
monly available drugs prescribed in an off-label manner after rational selection based on their putative ability
to correct the specific defect of neuromuscular transmission. While this means that there is a lack of evidence
meeting the CEBM’s higher level evidence categories, the review clearly shows that there is a substantial body
of both expert opinion and case-based analysis available and that in many cases, significant efforts have been
made to gather substantially sized cohorts for prospective or retrospective analysis [37,38,41,42]. This demon-
strates that it is valuable to systematically assess and categorize the evidence that does exist: clinicians make
daily treatment decisions that involve giving patients with CMS a pharmacological therapy, and providing
better access to the evidence in support of those decisions is not only of practical benefit to those making the
prescribing decisions, but also provides a gap analysis and guidance towards possible future options for clinical
trials.
Even with comprehensive genetic testing, ∼20–40% of patients with CMS remain genetically undiagnosed
[39]. Here, our systematic review cannot provide high-quality evidence for treatment decisions. Nevertheless,
expert opinion generally favors a continuation of the historically applied principle of trialing treatments already
known to be effective in other subtypes, following clinical decision trees based on phenotypic presentation and
clinical insights into potential mechanisms [43]. A similar approach applies where there is an urgent treatment
need while genetic results are pending, such as in cases of respiratory crisis and intensive care treatment, since
the beneficial effect of the correct treatment has the potential to dramatically improve outcomes.
Most of the treatments used in CMS are based on a scientific rationale derived from a detailed understanding
of the molecular and cellular pathophysiology of the neuromuscular junction that has been tested in cell and
animal models [44]. In humans, widely available drug treatments were applied off-label based on scientific
rationale (e.g. AChE inhibitors to increase availability of acetylcholine in the synaptic cleft) or serendipitous dis-
covery (e.g. ephedrine, which was found to offer symptomatic relief in autoimmune myasthenia gravis) long
before genetic confirmation became available. Some of these drugs have been the mainstay of CMS care in
expert centers for over 30 years [45]. As our review confirms, randomized, placebo-controlled trials are almost
entirely lacking, and clinical evidence is derived from a limited number of prospective and retrospective case
series and a much larger number of individual and familial case reports, which have resulted in the generation
of consensus opinion recommendations and expert reviews. Given the small number of individuals affected by
any CMS type, and especially the rarest types, it is unrealistic to expect that randomized controlled trials are a
likelihood in most cases. However, open-label studies where a patient is more systematically assessed using vali-
dated outcome measures before and after treatment might be a more realistic possibility, as is the publication
of larger retrospective studies following the examples of some of the case series assessed here.
Towards a treatabolome
Using the example of CMS, the systematic review presented in this paper shows that a wealth of knowledge
linking therapeutic options for rare diseases directly with the genotype is potentially available to clinicians and
geneticists. However, such knowledge is embedded in expert centers rather than in general practice, and while
some of it makes its way into scientific publications as captured in this review, it is not readily available to clin-
icians at the moment they are confronted with a particular patient, as they cannot be expected to perform a lit-
erature review on the fly or to be an expert in every one of the more than 7000 currently known rare diseases.
We therefore propose the development of a new curated knowledge base that links genetic variants with
therapeutic options in an interoperable form that facilitates incorporation into genomic analysis environments
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and clinical decision-support systems. This database, which we call the treatabolome, will contain a catalog of
treatable genes/variants and associated treatment strategies for the diseases covered. The treatabolome will
include all the relevant information for flagging the gene/variant in appropriate circumstances and providing
evidence details to allow the clinician to evaluate whether the treatment should be further investigated.
The need for a regularly updated database of this kind is further increased by the dynamic nature of treat-
ment recommendations, which may change over time as information evolves based on additional clinical
experience and new gene discoveries. One reason for these changes is the growth over the past decade of NGS
technologies that have dramatically increased the number of diagnosed rare diseases [46]. Its welcome expan-
sion within healthcare systems worldwide will further increase diagnostic rates for both known and novel rare
genetic disorders by making it easier to detect the genetic defect through non-targeted screening across the
whole genome, even in cases where symptoms are unspecific or atypical and the correct diagnosis was not sus-
pected by the geneticist or the clinician who ordered the test. The early and accurate diagnosis that NGS facili-
tates is of particular benefit in cases where dietary or enzyme replacement treatment from birth can slow or
prevent deterioration, as is the case for several rare metabolic disorders and vitamin- and cofactor- deficiencies,
and in cases where sudden and potentially fatal crises can arise in early childhood, including channelopathies
and the episodic apnea that is a feature of some types of CMS. In our experience with neuromuscular disorders
generally and CMS more specifically, the initiation of treatment is often delayed or treatment opportunities
may be missed completely with negative consequences for the patients. While a correct interpretation of NGS
results and an accurate molecular diagnosis is relevant for all families with rare genetic disease to support clin-
ical decision-making and counseling, it is even more important where effective treatments are available that can
be initiated upon reaching a diagnosis.
Motivated by these considerations, the CMS treatabolome will make variants in CMS-associated genes
readily visible to non-disease-expert users of genetic databases, NGS analysis platforms, and gene-based deci-
sion systems, and flag up their potential treatment relevance and the existing evidence supporting it. It will be
possible to incorporate the data into such systems through application programming interfaces or web services
as envisaged in Figure 3 in order to highlight it to the end-user during use of the system, for example, at the
time candidate variants are being assessed for pathogenicity. This will allow variants in treatable genes to be
prioritized for timely follow-up and interpretation in the clinical and phenotypic context.
In terms of content and structure, the treatabolome will include items such as inheritance (recessive or dom-
inant); penetrance (are there mutation carriers that do not develop the symptoms); severity (mild, severe/disab-
ling, and life-limiting); age of onset (neonatal, childhood, and adult), and associated ontological terms from the
Orphanet nomenclature and human phenotype ontology. Each genetic entry is connected to information about
Figure 3. Mock-up of integration of treatabolome into the analysis system.
(A) A section of the current analysis results interface in the RD-Connect Genome-Phenome Analysis Platform, which includes a range of
variant-level information that helps the user to assess which of the candidate variants is most likely causative. (B) The way it would be possible to
incorporate an additional column into the results interface to show the clinical end-user that one of the variants they are assessing has a potential
treatment associated, enabling them to evaluate the evidence base to decide whether it is appropriate for the patient in question.
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the treatment, such as treatment type (medication or other, e.g. diet and supplement); evidence (medication
licensed for this gene/indication; unlicensed but in clinical guidelines); effect size of the treatment (curative,
symptom-free, ameliorating symptoms, and extending lifespan); treatment indicated for asymptomatic (i.e. pre-
ventive) or symptomatic stages or specific symptoms/stages only; and a link to the relevant literature/resource.
The development of the treatabolome poses many challenges, especially with regard to curation, and will
require expert input from both the clinical domain and the computational and data stewardship domain. Even
this CMS systematic review, which started off with nearly 1000 studies to evaluate, covers only a small fraction
of the currently known rare diseases and known causative variants, and the number is constantly growing,
meaning that the database will need regular updates to remain relevant. Nevertheless, major online databases
requiring constant curation such as Orphanet [47], ClinVar [48], LOVD [49], and others have run successfully
in this domain for many years thanks to buy-in and substantial curation efforts from community experts, while
international initiatives such as the International Rare Diseases Research Consortium [50], the Global Alliance
for Genomics and Health [51], and RD-Connect [52] have shown that it is possible to bring expert working
groups together internationally to achieve specific goals that can be transformational for the field. The same
must be done for the linkage of variant information with treatment options: investment into the curation effort
from the clinical and domain experts must be paired with data stewardship and interoperability expertise to
generate a dataset that is compliant with the FAIR principles of findability, accessibility, interoperability, and
reusability [53] and that has buy-in from the expert community.
The information on CMS treatments linked to the underlying CMS genetic defects that we provide here will
be used to create a limited, pilot version of the treatabolome, which will be both interoperable and
machine-readable [54] and will be suitable for incorporation into genetic databases and NGS analysis systems as
guidance for end-users. The treatabolome concept will be applied to all rare neuromuscular disorders in future
studies and extended to other rare genetic diseases as required, in particular under the auspices of the European
Reference Networks, which provide a strategic framework for sharing of expertise in rare disease [55].
It is important to reiterate that the CMS treatabolome is not designed to replace clinical judgment by the
experienced neuromuscular specialist. Instead, by flagging up potentially treatable conditions and providing
immediate access to the evidence behind the result and the quality of the given evidence, it will assist the iden-
tification of treatable patients and support treatment decisions by better informing the treating clinician.
Conclusion
Congenital myasthenic syndromes are very rare and highly heterogeneous, which makes traditional clinical
trials to determine the efficacy and safety of medications difficult or impossible. This systematic review draws
on small case series and case reports that form the basis of expert opinion indicating that highly effective drug
treatments for various CMS subtypes exist, particularly AChE inhibitors and β2 adrenergic receptor agonists.
Many CMS patients remain undiagnosed for years and treatment is delayed or may not be initiated even after
exome sequencing if variants in CMS-associated genes are overlooked, have not been assigned as pathogenic in
relation to the phenotype, or are not appreciated for their treatment relevance. This systematic review sum-
marizes current knowledge about CMS treatments in relation to the underlying genetic defects and builds the
foundation for an interoperable knowledgebase — the treatabolome — that will be used to support the identifi-
cation of treatable variants at the time of diagnosis in genomic analysis systems such as RD-Connect. The trea-
tabolome concept and bioinformatic scaffold will be rolled out more broadly to other rare genetic conditions
through international collaborative efforts such as Solve-RD and the European Reference Networks.
Summary
• A significant number of rare diseases are treatable with marketed therapies or commonly avail-
able drugs, but ensuring that patients receive the appropriate treatment in a timely manner
remains challenging and requires new technologies suitable for the genomic era to support
clinicians in accessing the relevant information.
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• Very little high-level evidence exists for the drug treatment of congenital myasthenic syn-
dromes (CMS), but an increasing body of expert opinion based on clinical evidence suggests
that highly efficacious treatments do exist for the majority of patients and that treatment must
be tailored to the underlying genetic defect. Here, we link genotype with treatment information
for all CMS subtypes based on a systematic review of over 200 publications on more than
1000 patients.
• While expert opinion and systematic reviews may provide guidance and better access to evi-
dence, finding the best treatment for an individual patient involves complex decision pro-
cesses that remain the responsibility of an experienced clinician. Further prospective and
controlled studies of treated CMS patients are required to provide better evidence for the
long-term safety and efficacy of medications commonly used off-label.
• Next-generation sequencing is increasingly used as a first-line diagnostic tool for patients with
unspecific neuromuscular complaints or weakness, some of whom may be affected by CMS.
To alert the treating geneticist or clinician about patients with this highly treatable condition at
the time of reviewing NGS results, we will integrate the information from this systematic review
into a computer-readable and interoperable knowledgebase, the treatabolome, and expand
the concept to other rare diseases with the buy-in of domain experts.
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